EUVIMEDEUVIMED entdecken
Crossref

Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy

Hongfeng Gu, Wenxin Yan, Jieping Yang, Beibei Liu, Xiaolin Zhao, Hongxia Wang, Wenbo Xu, Chenghao Wang, Yang Chen, Qiuyi Dong, Qihua Zhu iD, Yungen Xu iD und 1 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.3c01764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Hongfeng Gu und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: China Pharmaceutical University, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PARP7 plays a crucial role in cancer immunity. The inhibition of PARP7 has shown potential in boosting the immune response against cancer, making it an attractive target for cancer immunotherapy. Herein, we employed a rigid constraint strategy (reduction in molecular flexibility) to design and synthesize a series of novel indazole-7-carboxamide derivatives based on the structure of RBN-2397. Among these derivatives, (S)-XY-05 was identified as the most promising PARP7 inhibitor (IC50: 4.5 nM). Additionally, (S)-XY-05 showed enhanced selectivity toward PARP7 and improved pharmacokinetic properties (oral bioavailability: 94.60%) compared with RBN-2397 (oral bioavailability: 25.67%). In the CT26 syngeneic mouse model, monotherapy with (S)-XY-05 displayed a strong antitumor effect (TGI: 83%) by activating T-cell-mediated immunity within the tumor microenvironment. Collectively, we confirmed that (S)-XY-05 has profound effects on tumor immunity, which paves the way for future studies of PARP7 inhibitors that could be utilized in cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsPoly(ADP-ribose) Polymerase InhibitorsAnimalsMiceCell Line, TumorImmunity, CellularIndazolesPoly(ADP-ribose) Polymerases

Substanzen

Indazoles2,3,7,8-tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase, mousePoly(ADP-ribose) PolymerasesPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
  • Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China.

ORCID-Profile: Qihua Zhu, Yungen Xu, Yi Zou

Förderung

  • China Pharmaceutical University
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Gu, H., Yan, W., Yang, J., Liu, B., Zhao, X., Wang, H., Xu, W., Wang, C., Chen, Y., Dong, Q., Zhu, Q., Xu, Y., & Zou, Y. (2024). Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01764

Vancouver

Gu H, Yan W, Yang J, Liu B, Zhao X, Wang H, et al. Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01764

BibTeX
@article{Gu2024,
  author = {Gu, Hongfeng and Yan, Wenxin and Yang, Jieping and Liu, Beibei and Zhao, Xiaolin and Wang, Hongxia and Xu, Wenbo and Wang, Chenghao and Chen, Yang and Dong, Qiuyi and Zhu, Qihua and Xu, Yungen and Zou, Yi},
  title = {Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.3c01764}
}
Kostenlos starten →